SCHEMBL4715682

SCHEMBL4715682

CCOC(=O)c1cc2[nH]c(=O)ccc2n1Cc1cccc(C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MAPT P10636 9/20 0.49
THRB P10828 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NOD2 Q9HC29 1/20 0.49
NOD1 Q9Y239 1/20 0.49
F10 P00742 3/20 0.48
POLB P06746 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
TSHR P16473 1/20 0.47
ATM Q13315 1/20 0.47
KDM4E B2RXH2 4/20 0.47
HPGD P15428 2/20 0.47
NPSR1 Q6W5P4 2/20 0.43
MAPK1 P28482 1/20 0.43
PPARG P37231 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4717121 0.90 MAPT (0.58) ALDH1A1L3MBTL1MAPTSMN1; SMN2NOD2
SCHEMBL4713786 0.89 MAPT (0.50) ALDH1A1KMT2AMEN1MAPTSMN1; SMN2
SCHEMBL4716178 0.83 MAPT (0.47) ALDH1A1MAPTSMN1; SMN2NOD2NOD1
SCHEMBL4715652 0.81 MAPT (0.49) ALDH1A1L3MBTL1MAPTSMN1; SMN2NOD2
SCHEMBL12930104 0.81 NOD2 (0.67) ALDH1A1KMT2AMEN1L3MBTL1MAPT
SCHEMBL12930101 0.78 NOD2 (0.67) ALDH1A1KMT2AMEN1L3MBTL1MAPT
SCHEMBL3201430 0.78 NOD2 (0.63) ALDH1A1KMT2AMEN1L3MBTL1MAPT
SCHEMBL4713175 0.77 MAPT (0.46) ALDH1A1KMT2AMEN1L3MBTL1MAPT
SCHEMBL4789434 0.76 ALDH1A1 (0.53) ALDH1A1KMT2AMEN1L3MBTL1MAPT
SCHEMBL926630 0.75 NOD2 (0.56) ALDH1A1KMT2AMEN1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed
EP-1549648-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS Celltech R & D Limited (GB) 2005-07-06 EP disclosed
WO-2004031188-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 ALDH1A1 3407/4885KMT2A 2241/4885MEN1 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.